Table 3.
Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age (year) | ||||
≤60 vs. >60 | 1.374 (0.923-2.048) | 0.118 | ||
Gender | ||||
Female vs. Male | 1.224 (0.799-1.876) | 0.353 | ||
Primary tumor site | ||||
Colon vs. Rectum | 1.837 (1.235-2.732) | 0.003 | 2.174 (1.448-3.364) | <0.001 |
T stage | ||||
1-3 vs. 4 | 1.096 (0.746-1.611) | 0.639 | ||
N stage | ||||
0 vs. 1-2 | 1.955 (1.271-3.005) | 0.002 | 2.414 (1.552-3.754) | <0.001 |
Histological | ||||
Well/moderate vs. Poor | 1.472 (0.861-2.518) | 0.157 | ||
Liver metastases tumor size (cm) | ||||
≤2.3 vs. >2.3 | 1.476 (0.987-2.207) | 0.058 | ||
Liver metastases number | ||||
Single vs. Multiple | 1.685 (1.128-2.518) | 0.011 | 2.027 (1.343-3.058) | 0.001 |
Hepatic resection timing | ||||
Synchronous vs. Metachronous | 1.297 (0.871-1.930) | 0.200 | ||
CEA (ng/ml) | ||||
≤5 vs. >5 | 1.245 (0.829-1.870) | 0.290 | ||
CA199 (U/ml) | ||||
≤37 vs. >37 | 1.051 (0.659-1.678) | 0.834 | ||
AFU (U/L) | ||||
≤30.8 vs. >30.8 | 0.601 (0.367-0.984) | 0.043 | 0.438 (0.264-0.728) | 0.001 |
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; CA19-9, cancer antigen 19-9; AFU, alpha-l-fucosidase.